Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Willis-Ekbom Disease Clear all
Recruiting Not applicable Interventional

Blood Changes After Exercise in Restless Legs Syndrome

NCT06481176
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
12-Week RLS Exercise Program
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

NCT00422994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome

NCT04700683
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Noctrix Health NPNS device v1.0 - Active, Noctrix Health NPNS device v1.0 - Sham
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Downey, California • Menlo Park, California • San Ramon, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
44
States / cities
Peoria, Arizona • Scottsdale, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional

Yoga vs. Education for Restless Legs Syndrome: a Feasibility Study

NCT03570515
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Yoga, Educational film
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 6, 2026, 11:41 PM EDT
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

NCT00991276
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pregabalin, placebo, pramipexole
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS

NCT05196828
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
NTX100 Neuromodulation System
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
San Leandro, California • Colorado Springs, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spinal Cord Stimulation for Restless Legs Syndrome

NCT03539081
View directory record Official record
Conditions
Restless Legs Syndrome, Neuropathic Pain
Interventions
Dual-energy X-ray absorptiometry Scan, Laboratory Measurements, Blood Flow Measurement, Continuous Blood Pressure, Partial pressure of oxygen, Microneurography, Anthropometric Measurements, John Hopkins Restless Legs Severity Scale, Continuous Blood Pressure Diary
Diagnostic Test · Other · Behavioral
Lead sponsor
Marshall Holland
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 6, 2026, 11:41 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

NCT07061470
View directory record Official record
Conditions
ADHD, Sleep Problems
Interventions
Ferrous Sulfate, Placebo
Dietary Supplement · Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

NCT00363857
View directory record Official record
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
49
States / cities
Alabaster, Alabama • Birmingham, Alabama • Jasper, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Not applicable Interventional Results available

The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

NCT02642315
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Horizant
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 6, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional Results available

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

NCT03992196
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 6, 2026, 11:41 PM EDT
Not listed Phase 4 Interventional

Sublingual Apomorphine in Refractory Restless Legs Syndrome

NCT05529095
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Apomorphine Sublingual Film, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 6, 2026, 11:41 PM EDT
Not listed Phase 4 Interventional

Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome

NCT02424695
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Gabapentin Enacarbil (GEn), Placebo
Drug
Lead sponsor
Cleveland Sleep Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

NCT00263068
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 6, 2026, 11:41 PM EDT
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 6, 2026, 11:41 PM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

NCT01192503
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
rasagiline, placebo (sugar pill)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Pinellas Park, Florida • Augusta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854
View directory record Official record
Conditions
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions
Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 6, 2026, 11:41 PM EDT
Withdrawn Phase 4 Interventional

Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

NCT00584246
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pregabalin (Lyrica), Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)

NCT00225862
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
37
States / cities
Alabaster, Alabama • Jasper, Alabama • Peoria, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome

NCT00199446
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 6, 2026, 11:41 PM EDT
Completed Phase 4 Interventional

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome

NCT00373542
View directory record Official record
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
ropinirole CR-RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 6, 2026, 11:41 PM EDT